Phoenix PharmaLabs

Deal To Watch
BETA

Addressing the opioid crisis by developing potent, safe, non-addictive painkillers.

Analytics

Raised to Date: $339,701

Aggregate Commitments $
Platform

Netcapital

Start Date

01/31/2021

Close Date

03/23/2021

Min. Goal

$10,000

Max. Goal

$1,070,000

Min. Investment

$99

Security Type

Equity - Common

Funding Type

RegCF

Series

Seed

Pre-Money Valuation

$26,790,283

Weekly Commitments $
Status

Active

Reporting Date

02/24/2021

Days Remaining

26

% of Min. Goal

3,397%

% of Max. Goal

32%

Likelihood of Max
Avg. Daily Raise

$14,154

Momentum
Location

Woods Cross, Utah

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B2C

Margin

High

Capital Intensity

High

Business Type

Growth

Phoenix PharmaLabs, with a post-money valuation of $26,790,283, is Crowdfunding on NetCapital. The company is a preclinical drug discovery company dedicated to the development of potent, safe, non-addictive treatments for pain and addiction. John Lawson, PH.D. and Lawrence Toll, PH.D. founded Phoenix PharmaLabs. The crowdfunding round has a minimum raise of $10,000 and a maximum raise of $1,070,000. Phoenix PharmaLabs lead drug, PPL-103, has demonstrated in animal studies that it is a very potent painkiller (10x more potent than morphine), and is non-addictive, does not produce withdrawal, does not cause death from overdose at elevated doses, and causes no constipation.

Summary Profit and Loss Statement
Most Recent Year Prior Year

Revenue

$1,285,068

$66,654

COGS

$0

$0

Tax

$0

$100

 

 

Net Income

$-552,876

$-939,817

Summary Balance Sheet
Most Recent Year Prior Year

Cash

$761,206

$37,344

Accounts Receivable

$0

$0

Total Assets

$761,206

$37,344

Short-Term Debt

$0

$1,964,449

Long-Term Debt

$2,058,665

$0

Total Liabilities

$2,058,665

$1,964,449

Summary of Crowdfunding Raises
Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
03/23/2021 Netcapital $26,790,283 $339,701 Equity - Common Active RegCF
01/30/2021 Netcapital $26,790,283 $0 Equity - Common Confirmed Closed Test the Waters
03/30/2019 Netcapital $23,136,335 $1,102,553 Equity - Common Confirmed Closed RegCF

Ratings

last updated 02/25/2021

Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.

Analyst Report

Deal To Watch
Ratings Platform - Beta Trial

Our new ratings and analytics platform is currently in Beta. To gain access to the Beta platform features, upgrade to a Pro paid account and accept the Beta terms on any page.

For a limited time, use coupon code "TRYMERLIN20" for a free 20 day trial of Kingscrowd Pro and Merlin Beta. Your paid subscription will activate at the end of 20 days. Cancel anytime.
Other Deals

MedVector on StartEngine

The COVID-19 pandemic has grown the telehealth industry exponentially. A recent study of U.S medical specialists found that

Crowd
C-Reveal Therapeutics on NetCapital

Cancer is the great, mysterious killer of medical science. As of January 2019, there were an

Crowd
Millennial Fertility Co. on NetCapital

The Millennial Fertility Co. team has been selected as a “Deal to Watch” by KingsCrowd. This distinction is…

Crowd
Create your first portfolio
WELCOME TO YOUR OWN INVESTMENTS PORTFOLIO ON KINGSCROWD.

Now you can track all of your startup investments in one place utilizing our state-of-the-art portfolio tracker tools. To begin, create your first portfolio below.

Add to portfolio
Add Phoenix PharmaLabs on Netcapital
Follow company
Follow Phoenix PharmaLabs on Netcapital